Humacyte Ownership | Who Owns Humacyte?

Overview Forecast RevenueFinancials Chart Transcripts

Humacyte Ownership Summary

Humacyte is owned by 37.30% institutional investors, 9.13% insiders, and 53.57% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.79% of HUMA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.39% of its assets in Humacyte shares.

HUMA Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Humacyte	37.30%	9.13%	53.57%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock funding, inc. /de	12.32M	7.79%	$7.47M
Blackrock	7.14M	6.60%	$34.27M
Vanguard group	8.42M	5.32%	$8.09M
Antipodes partners	5.72M	3.62%	$3.47M
Great point partners	3.75M	2.37%	$2.28M
Geode capital management	3.66M	2.31%	$2.22M
State street	3.04M	1.92%	$1.85M
Ubs group	2.78M	1.76%	$1.69M
Woodline partners lp	2.00M	1.27%	$1.21M
Aqr capital management	1.92M	1.22%	$1.17M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Lion point capital, lp	650.00K	2.36%	$394.36K
Great point partners	3.75M	0.52%	$2.28M
Antipodes partners	5.72M	0.07%	$3.47M
Imprint wealth	16.36K	0.05%	$9.93K
Wealth effects	204.50K	0.04%	$124.07K
Endowment wealth management	105.42K	0.03%	$64.28K
Lji wealth management	277.50K	0.03%	$168.36K
R squared	62.91K	0.02%	$38.17K
Nverses capital	5.90K	0.02%	$28.32K
Clarus wealth advisors	39.97K	0.01%	$24.26K

Top Buyers

Holder	Shares	% Assets	Change
Antipodes partners	5.72M	0.07%	5.71M
Great point partners	3.75M	0.52%	3.75M
Blackrock	7.14M	0.00%	2.35M
Aqr capital management	1.92M	0.00%	1.89M
Vanguard fiduciary trust	1.01M	0.00%	1.01M

Top Sellers

Holder	Shares	% Assets	Change
Heights capital management	-	-	-4.03M
Ra capital management	-	-	-3.31M
Millennium management	108.15K	-	-2.52M
Morgan stanley	186.74K	-	-2.32M
Aigh capital management	-	-	-2.16M

New Positions

Holder	Shares	% Assets	Change	Value
Great point partners	3.75M	0.52%	3.75M	$2.28M
Vanguard fiduciary trust	1.01M	0.00%	1.01M	$613.70K
Ieq capital	264.32K	0.00%	264.32K	$160.36K
Gsa capital partners llp	249.86K	0.01%	249.86K	$152.00K
Mariner	106.28K	0.00%	106.28K	$64.47K

Sold Out

Holder	Change
Clearstead advisors	-7.00
Org partners	-10.00
Principal securities	-15.00
Transce3nd	-16.00
Gen-wealth partners	-85.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	163	7.24%	59,001,451	6.66%	37	3.06%	88	14.29%	31	-13.89%
Dec 31, 2025	100	-32.89%	41,097,732	-10.40%	25	2.98%	52	-10.34%	19	-57.78%
Sep 30, 2025	91	-41.67%	30,080,405	-43.82%	19	1.63%	36	-64.36%	27	12.50%
Jun 30, 2025	163	-6.86%	56,940,940	-6.40%	36	1.71%	104	8.33%	26	-29.73%
Mar 31, 2025	176	2.92%	61,024,544	45.00%	46	3.74%	97	-	37	-7.50%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	5.30M	2.39%	-
iShares Russell 2000 ETF	3.70M	1.67%	31.21K
SPDR® S&P Biotech ETF	2.26M	1.43%	5.04K
Vanguard Institutional Extnd Mkt Idx Tr	1.81M	0.81%	109.72K
Fidelity Small Cap Index	1.52M	0.68%	8.50K
iShares Biotechnology ETF	1.43M	0.64%	231.70K
Nuveen Quant Small Cap Equity R6	728.27K	0.61%	-
iShares Russell 2000 Value ETF	1.10M	0.49%	5.92K
MEDICAL BioHealth EUR Acc	718.45K	0.45%	-
State St Russell Sm/Mid Cp® Indx SL Cl I	957.62K	0.43%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 19, 2026	Sebelius Kathleen	-	Buy	$50.00K
May 18, 2026	Constantino Michael T.	-	Buy	$9.84K
May 18, 2026	Sander Dale A.	CFO and Chief Corp. Dev. Off	Sell	$41.15K
May 18, 2026	Parikh Shamik J	Chief Medical Officer	Sell	$41.15K
Aug 20, 2025	Dougan Brady W	-	Sell	$934.86K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	2	2
2025 Q4	-	-
2025 Q3	-	6
2025 Q2	6	-
2025 Q1	-	-

HUMA Ownership FAQ

Who Owns Humacyte?

Humacyte shareholders are primarily institutional investors at 37.30%, followed by 9.13% insiders and 53.57% retail investors. The average institutional ownership in Humacyte's industry, Biotech Stocks , is 35.75%, which Humacyte exceeds.

Who owns the most shares of Humacyte?

Humacyte’s largest shareholders are Blackrock funding, inc. /de (12.32M shares, 7.79%), Blackrock (7.14M shares, 6.60%), and Vanguard group (8.42M shares, 5.32%). Together, they hold 19.70% of Humacyte’s total shares outstanding.

Does Blackrock own Humacyte?

Yes, BlackRock owns 6.60% of Humacyte, totaling 7.14M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 34.27M$. In the last quarter, BlackRock increased its holdings by 2.35M shares, a 49.10% change.

Who is Humacyte’s biggest shareholder by percentage of total assets invested?

Lion point capital, lp is Humacyte’s biggest shareholder by percentage of total assets invested, with 2.36% of its assets in 650K Humacyte shares, valued at 394.36K$.

Who is the top mutual fund holder of Humacyte shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Humacyte shares, with 2.39% of its total shares outstanding invested in 5.3M Humacyte shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools